Actively Recruiting

Phase 2
Age: 55Years - 80Years
All Genders
NCT04838301

Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

Led by University of Arizona · Updated on 2026-03-13

100

Participants Needed

10

Research Sites

187 weeks

Total Duration

On this page

Sponsors

U

University of Arizona

Lead Sponsor

N

National Institute on Aging (NIA)

Collaborating Sponsor

AI-Summary

What this Trial Is About

A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.

CONDITIONS

Official Title

Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

Who Can Participate

Age: 55Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Men and postmenopausal women
  • Age 55 to 80 years old
  • Meets NIA-AA criteria for probable Alzheimer's disease dementia
  • Mini-Mental State Exam (MMSE) score of 20 to 26
  • Positive plasma p-Tau217 test
  • Geriatric Depression Scale short form (GDS-S) score of 6 or less
  • No medical reasons preventing participation
  • Able to give informed consent at screening
Not Eligible

You will not qualify if you...

  • Dementia other than probable Alzheimer's disease
  • Use of benzodiazepines, anticonvulsants, antipsychotics, or drugs interacting with GABA-A receptor
  • History of stroke with modified Hachinski Ischemic Scale score greater than 4
  • History of seizure disorder, focal brain lesion, or traumatic brain injury
  • Cancer diagnosis within the last 5 years
  • Unstable or serious heart, kidney, or liver disease
  • MRI showing significant brain abnormalities including ARIA-E, multiple microhemorrhages, encephalomalacia, aneurysms, vascular malformations, subdural hematoma, or lesions
  • Any conditions preventing MRI studies
  • No signs of Alzheimer's-type brain atrophy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 10 locations

1

Perseverance Research Center

Scottsdale, Arizona, United States, 85253

Actively Recruiting

2

University of Arizona / Clinical & Translational Sciences Research Center

Tucson, Arizona, United States, 85721

Actively Recruiting

3

ATP Clinical Research

Costa Mesa, California, United States, 92626

Actively Recruiting

4

Wake Research-PRI, LLC

Los Alamitos, California, United States, 90720

Withdrawn

5

Syrentis Clinical Research

Santa Ana, California, United States, 92705

Terminated

6

Optimus U Corporation

Miami, Florida, United States, 33135

Actively Recruiting

7

Miami Jewish Health

Miami, Florida, United States, 33137

Actively Recruiting

8

Combined Research Orlando

Orlando, Florida, United States, 32807

Terminated

9

Conquest Research

Winter Park, Florida, United States, 32789

Actively Recruiting

10

MedVadis Research

Waltham, Massachusetts, United States, 02451

Actively Recruiting

Loading map...

Research Team

C

Claudia M Lopez, BS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease | DecenTrialz